Screener
Revolution Medicines, Inc. RVMD Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Exercise of warrants | 57 | 1 |
| Deferred offering costs | (252) | (18) |
| Net cash provided by financing activities | 238,744 | 874 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 57,194 | (209,510) |
| Cash, cash equivalents and restricted cash - beginning of period | 388,603 | 546,762 |
| Cash, cash equivalents and restricted cash - end of period | $445,797 | $337,252 |
| Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets | ||
| Cash and cash equivalents | 440,939 | 333,554 |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s net change in cash?
- Revolution Medicines, Inc. (RVMD) reported net change in cash of $57.19M in Q1 2026.
- How has Revolution Medicines, Inc.'s net change in cash changed year-over-year?
- Revolution Medicines, Inc.'s net change in cash increased by 127.3% year-over-year, from -$209.51M to $57.19M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Revolution Medicines, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude